TMEM16A in prostate cancer: mechanistic insights and therapeutic implications

TL;DR

This paper reviews TMEM16A's role in prostate cancer, showing it promotes cancer growth and could be a new treatment target.

Contribution

The paper provides mechanistic insights into TMEM16A's role in prostate cancer progression and its potential as a therapeutic target.

Findings

TMEM16A is overexpressed in metastatic prostate cancer and linked to poor clinical outcomes.

Inhibiting TMEM16A shows promise in preclinical studies for treating prostate cancer.

TMEM16A is involved in cancer cell proliferation and invasion via pathways like MAPK.

Abstract

Transmembrane protein 16A (TMEM16A), functions as a calcium-activated chloride channel and has been recognized as a crucial factor in the pathophysiological processes of prostate cancer. Its elevated expression in metastatic prostate cancer cell lines is associated with unfavorable clinical outcomes, indicating its potential use as both a biomarker and a therapeutic target. This review emphasizes TMEM16A's involvement in facilitating cancer cell proliferation, migration, and invasion via various signaling cascades, notably the MAPK pathway. The inhibition of TMEM16A has yielded encouraging results in preclinical studies, highlighting its promise as a target for innovative therapeutic approaches. Additionally, examining TMEM16A's involvement in benign prostatic hyperplasia (BPH) enhances our comprehension of its relevance to prostatic health. Future investigations should focus on clarifying the fundamental mechanisms underlying TMEM16A's role and assessing its clinical applicability across various cancer types.

Figures